Company Overview
Company Type: Public Company
Website: www.inmedpharma.com
Number of Employees: 13
Ticker: INM (NasdaqCM)
Year Founded: 1981


Business Description
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
5.7
Market Capitalization
3.1
TEV/Total Revenue
NM
EBITDA
(11.2)
Total Enterprise Value
(8.7)
TEV/EBITDA
NM
EBIT
(11.5)
Cash & ST Invst.
12.3
P/Diluted EPS Before Extra
NM
Net Income
(10.9)
Total Debt
0.5
Price/Tang BV
0.2x
Capital Expenditure
(0.2)
Total Assets
19.4
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023


Estimates Snapshot (Current Fiscal Year End: Jun-30-2024 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
Revenue (mm)
1.89
2.37
10.92
13.65
10.92

Forward Multiples (Current FY)

TEV/REV
NM

Non-Periodic Estimates

Recommendation
No Opinion (0.00)


Key Professionals
Name
Title
Adams, Eric A.
President, CEO & Director
Hossain, Sazzad 
Co-Founder
Tegge, Jonathan R.
Interim Chief Financial Officer
Woudenberg, Michael 
Chief Operating Officer
Li, Sarah 
VP of Accounting & Controller
Clancy, Colin 
Senior Director of Investor Relations
Griffin, Jerry P.
Vice President of Sales & Marketing
Hsu, Eric Chih-Hsien
Senior Vice President of Preclinical Research & Development
Johnson, Shane A.
Senior VP & GM of BayMedica
Mancini, Alexandra Diane-Janet
Senior Vice President of Clinical & Regulatory Affairs
Muhammad, Ado 
Senior Consultant of Medical Affairs

Key Board Members
Name
Title
Hull, Andrew 
Independent Chair of the Board
Adams, Eric A.
President, CEO & Director
Baldasare, Bryan
Independent Director
Grove, Janet 
Independent Director
Lemerond, Nicole 
Independent Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
815 West Hastings Street Suite 310 | Vancouver, BC | V6C 1B4 | Canada
Phone: 604 669 7207    Fax: 778 945 6800

Current and Pending Investors
Armistice Capital LLC, Ayrton Capital LLC, Boothbay Fund Management, LLC, Empery Asset Management, LP, Hudson Bay Capital Management LP, Intracoastal Capital LLC, Sabby Management, LLC, Terminal City Capital Inc., The Bigger Capital Fund, LP, The Lind Partners, LLC

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.93
Market Cap (mm)
3.1
Open
 1.00
Shares Out. (mm)
3.3
Previous Close
 0.93
Float %
99.5%
Change on Day
0.0014
Shares Sold Short (mm)
0.0
Change % on Day
0.1%
Dividend Yield %
-
Day High/Low
 1.00/ 0.89
Diluted EPS Excl. Extra Items
(4.46)
52 wk High/Low
 12.03/ 0.87
P/Diluted EPS Before Extra
NM
Volume (mm)
0.04
Avg 3M Dly Vlm (mm)
0.05
Beta 5Y
0.91


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
NasdaqCM:INM - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
BayMedica, Inc.
BayMedica Inc. develops a proprietary platform to produce high quality, rare cannabinoids for consumer applications and cannabinoid-derived new chemical entities for pharmaceutical applications. The company was incorporated in 2016 and is based in Incline Village, Nevada. As of October 13, 2021, BayMedica Inc. operates as a subsidiary of InMed Pharmaceuticals Inc.

United States and Canada
Health Care Technology
-
-
-
Biogen Sciences Inc.
Biogen Sciences Inc. operates as a biopharmaceutical company that offers drug discovery and development of the therapeutic science of cannabinoids. The company is based in British Columbia, Canada. As of May 10, 2014, Biogen Sciences Inc. operates as a subsidiary of InMed Pharmaceuticals Inc.

United States and Canada
Pharmaceuticals
-
-
-
Time Search Inc.
Time Search Inc., doing business as Calgoo Software, provides calendar, scheduling, and collaboration solutions to aggregate, synchronize, and access multiple calendar platforms for the small businesses and consumers. Its products include In-Calendar Marketing, which enables businesses to promote time-sensitive products and services to their customers; Calgoo Hub, a calendar sharing service that connects people with calendars of family, friends, and colleagues; Calgoo Calendar, which manages multiple calendars and contacts; Calgoo Connect, a calendar synchronize tool that supports synchronization between a wide range of calendar programs; and Calgoo Core, which allows software developers to aggregate, synchronize, and access multiple calendar platforms. The company was founded in 2006 and is based in Vancouver, Canada. As per the transaction announced on February 20, 2009, Time Search Inc. operates as a subsidiary of Meridex Software Corp.

United States and Canada
Application Software
-
-
-
Savicon, Inc.
Savicon, Inc. provides solutions for integrated building security; camera monitoring; heating, ventilation, and air conditioning; and lighting control. It offers camera monitoring solutions, which is designed for personal and small business use. The company’s system components include The Entegrator, which communicates with cameras, storing searchable images, and writing digital video discs, as well as enables wireless viewing and control; TouchPad, which enables to access camera monitoring views; system display; and security cameras. Savicon, Inc. is based in Garden City, Idaho. As of November 15, 2007, Savicon, Inc. is a subsidiary of Meridex Software Corporation.

United States and Canada
Systems Software
-
-
-
0728309 BC Inc.
As of October 11, 2005, 0728309 BC Inc. was acquired by Meridex Software Corp. 0728309 BC Inc. is based in Canada.

United States and Canada
-
-
-
-
SDM Enterprises Inc.
SDM Enterprises, Inc. provides facility management solutions. Its products include ARCHIBUS/FM NAVIGATOR, a computer-aided facilities management solution that guides step-by-step through facilities management procedures by showing where to start, what to enter, and what types of reports can derive from the information; Web-accessible facility management solutions; and barcode inventory systems. These products provide access to information on space utilization, personnel tracking, communication systems, furniture inventory, and layout. The company serves finance, telecommunications, data processing, aerospace, health care, and education industries. SDM Enterprises was founded in 1983 and is based in San Marcos, Texas. As of June 27, 2005 SDM Enterprises, Inc. is a subsidiary of Meridex Software Corporation.

United States and Canada
Application Software
-
-
-
AssistGlobal Inc.
AssistGlobal, Inc. provides hosted solutions for project and facility management software applications. Its services include custom application development and deployment, and enterprise systems integration. The company offers ARCHIBUS/FM, a commercial off-the-shelf for facilities management and asset management automation; FM Studio, a Web-based facilities data viewer; MicroView FM, a bi-directional palm interface to ARCHIBUS/FM; MicroView Electrical module; and MicroView HVAC module. It serves facilities, infrastructure, and project management industries. The company, formerly known as AssistGlobal.com Communications, Inc., was founded in 2000 and is based in Burnaby, Canada. As of June 24, 2005 AssistGlobal, Inc. is a subsidiary of Meridex Software Corporation.

United States and Canada
Application Software
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Dec-7-2022
Dec-15-2022
Shelf Registration
Target
InMed Pharmaceuticals Inc. (NasdaqCM:INM)

 Seller Funds:Armistice Capital Master Fund Ltd., Sabby Volatility Warrant Master Fund, Ltd.
12.37
Nov-17-2022
Nov-21-2022
Private Placement
Target
InMed Pharmaceuticals Inc. (NasdaqCM:INM)


6.00
Nov-14-2022
-
Shelf Registration
Target
InMed Pharmaceuticals Inc. (NasdaqCM:INM)


0.24
Oct-11-2022
Oct-19-2022
Shelf Registration
Target
InMed Pharmaceuticals Inc. (NasdaqCM:INM)

Armistice Capital, LLC (nka:Armistice Capital LLC),Sabby Management, LLC Seller Funds:Armistice Capital Master Fund Ltd., Sabby Volatility Warrant Master Fund, Ltd.
14.08
Sep-09-2022
Sep-13-2022
Private Placement
Target
InMed Pharmaceuticals Inc. (NasdaqCM:INM)


6.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-29-2023
Delayed SEC Filings
InMed Pharmaceuticals Inc. announced delayed annual 10-K filing
Sep-28-2023
Company Conference Presentations
InMed Pharmaceuticals Inc. Presents at Benzinga Cannabis Capital Conference 2023, Sep-28-2023 11:40 AM
Sep-25-2023
Delistings
InMed Pharmaceuticals Inc. Receives Non-Compliance Notice From Nasdaq
Sep-11-2023
Company Conference Presentations
InMed Pharmaceuticals Inc. Presents at H.C. Wainwright 25th Annual Global Investment Conference, Sep-11-2023 07:00 AM
Jul-25-2023
Special Calls
InMed Pharmaceuticals Inc. - Special Call

M&A Advisors
Fasken Martineau DuMoulin LLP, Norton Rose Fulbright US LLP


Advisors
Most Recent Auditor
Marcum LLP
M&A Advisors
Fasken Martineau DuMoulin LLP, Norton Rose Fulbright US LLP
Private Placement Advisors
Canaccord Genuity Group Inc. (TSX:CF), H.C. Wainwright & Co., LLC, Norton Rose Fulbright Canada LLP, ROTH Capital Partners, LLC
Public Offering Advisors
Anton, Bryson & Schindler Chartered Professional Accountants LLP, Dorsey & Whitney LLP, Farris, Vaughan, Wills & Murphy LLP, H.C. Wainwright & Co., LLC, KPMG LLP, KPMG LLP (Canada), Norton Rose Fulbright Canada LLP, Norton Rose Fulbright US LLP
Key development Advisor
Midtown Partners & Co., LLC, Pharus Securities, LLC


Most Recent Auditor
Marcum LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

03:21 AM
INM
InMed Pharmaceuticals Inc 2023_10_05
Reports
14
Water Tower Research LLC
Sassoon, Robert
Sep 15, 2023 08:50 AM
INM
White Paper Highlights Attributes of CBC
Notes
5
GlobalData

Sep 15, 2023 05:01 AM
INM
InMed Pharmaceuticals Inc (INM.NASD) - Medical Devices Product Pipeline Summary
Reports
54
GlobalData

Sep 14, 2023 11:55 PM
INM
InMed Pharmaceuticals Inc (INM.NASD) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
68
MarketLine

Sep 14, 2023 06:01 AM
INM
InMed Pharmaceuticals Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
Reports
202
GlobalData

Sep 12, 2023 03:39 AM
INM
InMed Pharmaceuticals Inc (INM.NASD) - Financial Analysis Review
Reports
334
S&P Global Compustat

Sep 07, 2023 03:06 AM
INM
InMed Pharmaceuticals Inc 2023_09_07
Reports
14
GlobalData

Aug 25, 2023 03:22 AM
INM
InMed Pharmaceuticals Inc (INM.NASD) - Medical Equipment - Deals and Alliances Profile
Reports
45
GlobalData

Aug 25, 2023 03:21 AM
INM
InMed Pharmaceuticals Inc (INM.NASD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
86
Pechala's Reports

Aug 04, 2023 11:00 PM
INM
INMED PHARMACEUTICALS INC COMMON (INM=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS
Reports
2


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Susquehanna International Group, LLP, Asset Management Arm

13,672

0.41

0.0

Jun-30-2023


Johnson Ph.D., Shane A.

12,183

0.37

0.0

Sep-07-2022


Adams B.S. Chem., M.I.B., Eric A.

2,359

0.07

0.0

Mar-08-2023


Bank of America Corporation, Asset Management Arm

1,834

0.06

0.0

Jun-30-2023


Hull B.A., Andrew 

758

0.02

0.0

Oct-24-2022


Geode Capital Management, LLC

582

0.02

0.0

Aug-31-2023


Colwill C.A., CPA, CA, Bruce S.

461

0.01

0.0

Oct-24-2022


Mancini M.Sc., Alexandra Diane-Janet

240

0.01

0.0

Mar-08-2023


Hsu, Eric Chih-Hsien

51

0.00

0.0

Aug-31-2023


BlackRock, Inc.

50

0.00

0.0

Jun-30-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Geode Capital Management, LLC
582
30
Bank of America Corporation, Asset Management Arm
1,834
12
RBC Dominion Securities Inc., Asset Management Arm
18
7
SagePoint Financial Advisors, Inc., Securities Investments
19
1

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Renaissance Technologies LLC
0
(77,500)
Susquehanna International Group, LLP, Asset Management Arm
13,672
(5,147)
UBS Asset Management AG
0
(2,622)
Advisory Services Network, LLC
0
(6)
TCI Wealth Advisors, Inc., Asset Management Arm
0
(5)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
3CSafe, Cannabidivarin (Future), Consultation and Assessment Services, CT-091 (Future), CTI-805, Data Storage Solutions, Hardware and Software Upgrades Services, Implementation and Training Services, INM-088 (Future), INM-405 (Future), INM-755 (Future), IntegraSyn (Future), IP Surveillance Solution, IT Security Services, Meridex MicroView, Network Design and Configuration Services, Network Services, Sales of Computer Software, Sales of Hardware and Software Products, Scheduled Services, Technical Support Services, Tetrahydrocannabivarin (Future)


Upcoming Events
Date/Time
Type
Nov-10-2023
Estimated Earnings Release Date (S&P Global Derived)
Dec-19-2023
Annual General Meeting
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-29-2023
Sep-29-2023
InMed Pharmaceuticals Inc. (NasdaqCM:INM)
SEC
8-K (7.01, 9.01)
376 KB
Sep-29-2023
-
InMed Pharmaceuticals Inc. (NasdaqCM:INM)
SEDAR
News Releases
60 KB
Sep-29-2023
Jun-30-2023
InMed Pharmaceuticals Inc. (NasdaqCM:INM)
SEDAR
Annual Financial Statements
578 KB
Sep-29-2023
Jun-30-2023
InMed Pharmaceuticals Inc. (NasdaqCM:INM)
SEC
10-K
8 MB
Sep-29-2023
Jun-30-2023
InMed Pharmaceuticals Inc. (NasdaqCM:INM)
SEC
NT 10-K
38 KB
Sep-25-2023
Sep-25-2023
InMed Pharmaceuticals Inc. (NasdaqCM:INM)
SEC
8-K (8.01, 9.01)
272 KB
Sep-25-2023
-
InMed Pharmaceuticals Inc. (NasdaqCM:INM)
SEDAR
Notice of the Meeting and Record Date
124 KB
Sep-25-2023
-
InMed Pharmaceuticals Inc. (NasdaqCM:INM)
SEDAR
Notice of the Meeting and Record Date
124 KB
Sep-25-2023
Sep-22-2023
InMed Pharmaceuticals Inc. (NasdaqCM:INM)
SEC
8-K (3.01)
242 KB
Sep-22-2023
-
InMed Pharmaceuticals Inc. (NasdaqCM:INM)
SEDAR
News Releases
33 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Adams B.S. Chem., M.I.B., Eric A. (President, CEO & Director)
Apr-14-2022
Common Shares
566
17,390
Open Market Acquisition
31.58
Multiple
Adams B.S. Chem., M.I.B., Eric A. (President, CEO & Director)
Apr-13-2022
Common Shares
342
9,995
Open Market Acquisition
16.71
Form 4
Colwill C.A., CPA, CA, Bruce S. (Former CFO & Corporate Secretary)
Jan-24-2022
Common Shares
200
7,471
Private Acquisition
76.63
Form 4
Johnson Ph.D., Shane A. (Senior VP & GM of BayMedica)
Jan-06-2022
Common Shares
340
14,713
Open Market Acquisition
2.87
Form 4
Johnson Ph.D., Shane A. (Senior VP & GM of BayMedica)
Dec-30-2021
Common Shares
323
14,749
Open Market Acquisition
2.81
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Hull, Andrew 
Independent Chair of the Board
604 669 7207 
778 945 6800

Adams, Eric A.
President, CEO & Director
(604) 306-6640
778 945 6800
eadams@inmedpharma.co
Baldasare, Bryan
Independent Director
604 669 7207 
778 945 6800
-
Grove, Janet 
Independent Director
604 669 7207 
778 945 6800

Lemerond, Nicole 
Independent Director
604 669 7207 
778 945 6800

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Adams, Eric A.
President, CEO & Director
(604) 306-6640
778 945 6800
eadams@inmedpharma.co
Hossain, Sazzad 
Co-Founder
604 669 7207 
778 945 6800

Tegge, Jonathan R.
Interim Chief Financial Officer
604 669 7207 
778 945 6800

Woudenberg, Michael 
Chief Operating Officer
604 669 7207 
778 945 6800

Li, Sarah 
VP of Accounting & Controller
604 669 7207 
778 945 6800

Clancy, Colin 
Senior Director of Investor Relations
+1 604 416 0999
778 945 6800
cclancy@inmedpharma.com
Griffin, Jerry P.
Vice President of Sales & Marketing
604 669 7207 
778 945 6800

Hsu, Eric Chih-Hsien
Senior Vice President of Preclinical Research & Development
604 669 7207 
778 945 6800

Johnson, Shane A.
Senior VP & GM of BayMedica
604 669 7207 
778 945 6800

Mancini, Alexandra Diane-Janet
Senior Vice President of Clinical & Regulatory Affairs
604 669 7207 
778 945 6800

Muhammad, Ado 
Senior Consultant of Medical Affairs
604 669 7207 
778 945 6800
-
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
